Medical technology has always been a sector with a high level of M&A activity in any given year. Large companies are always on the lookout for technologies and assets that can boost their growth rate, while a plethora of single-product/single-market outfits hope for the boon of a big-time payday. That said, 2010 was a bit of a disappointment in terms of deal activity. Though there certainly were notable deals throughout the year, the pace was slower than what most people predicted in late 2009. Perhaps, then, that means that 2011 will be an above-average year as economic recovery puts some life back into this lagging sector. (For more, see Where The M&A Action Is, And What's Next.)

IN PICTURES: 9 Simple Investing Ratios You Need To Know

The Gold Star Goes to Covidien
Covidien (NYSE:COV) was certainly among the most active players this year. Covidien started off by getting rid of most of its respiratory care business and then turning around and buying peripheral and neurovascular specialist ev3 for $2.6 billion. Shortly thereafter, Covidien decided to expand its monitoring business by acquiring Somanetics in a $300 million cash deal. Time will tell whether the company can leverage these deals into sustainably higher growth rates, but it seemed to help Covidien's stock do a little better on a relative basis. (For more, see Covidien - Better Than People Seem To Think.)

St. Jude Quietly Following the Medtronic Model
St. Jude (NYSE:STJ) still seems to carry a bad reputation from the days when it was the "other" company competing with Medtronic (NYSE:MDT) and Boston Scientific's (NYSE: BSX) Guidant in the pacemaker and ICD business. Nevertheless, St. Jude has quietly been building an interesting collection of businesses, largely through M&A. This year, St. Jude shelled out more than $1 billion to acquire AGA Medical and its cardiac repair business - a logical outgrowth of a company with interests in heart surgery, valve replacement, ablation, and other cardiology niches.

Medtronic Still Being Medtronic
Of course, it seems like there can never be a year of med-tech M&A that does not involve Medtronic. Curiously, though, the company took a different strategy to its M&A in 2010 - buying two small companies (Osteotech and ATS Medical) that had been public for quite a while and never really thrived despite having what was once thought of as solid technology. To a large extent, these may be "back-filling" acquisitions that fill in gaps in Medtronic's product line-up, but they are not the sort of bold initiatives that Medtronic is known for or that many investors expect. (For more, see A Checklist For Successful Medical Technology Investment.)

Boston Scientific Starts to Clean House
Boston Scientific has long tried to do many different things well and has largely failed as a public company as a result. 2010 may mark the start of a new trend, however, as the company began to shed some of its business units. The most notable move for BSX was the decision to sell its neurovascular business to Stryker (NYSE:SYK) for more than $1.4 billion. While there were rampant rumors of a deal between the two companies, most people thought Stryker would be buying the neurostimulation business - a unit that the company just recently took off the auction block.

GE Stretches Its Legs
General Electric (NYSE:GE) pricked up some investors' ears relatively late in the year when company executives began openly talking about putting some potentially large sums of capital to work in the health care space. So far, all of that talk has led to just one deal - the acquisition of oncology diagnostics specialist Clarient. It would hardly be surprising, though, to see GE get more active in the coming year, perhaps involving itself in the Beckman Coulter (NYSE:BEC) sale or the acquisition of a major life sciences or radiology company. (For related reading, see 5 Healthcare IT Stocks To Know.)

Setting the Stage for 2011
With Thermo Fisher (NYSE:TMO) announcing a deal for Dionex (Nasdaq:DNEX) late in the year, it is a good reminder that 2011 could be an active year for more life sciences M&A - with companies like Bruker (Nasdaq:BRKR), Luminex (Nasdaq:LMNX) and Caliper Life Sciences (Nasdaq:CALP) all looking like reasonable targets. Likewise, medical devices could certainly see activity in areas like orthobiologics, radiology, cardiology and diagnostics/imaging.

The more things change in med-tech, the more they stay the same. Big companies still want to find new avenues of growth and better sales leverage, and acquiring a smaller player is often cheaper than navigating the hazards of R&D, patents and the FDA. Likewise, small companies operate in the shadows of these giants - using novel approaches to treat disease and grow revenue, while often hoping to attract a premium buyout bid. With that in mind, and a generally more favorable operating environment, 2011 should be a busy year. (For more, see A Checklist For Successful Medical Technology Investment.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Stock Analysis

    3 Stocks that Are Top Bets for Retirement

    These three stocks are resilient, fundamentally sound and also pay generous dividends.
  2. Investing News

    Are Stocks Cheap Now? Nope. And Here's Why

    Are stocks cheap right now? Be wary of those who are telling you what you want to hear. Here's why.
  3. Investing News

    4 Value Stocks Worth Your Immediate Attention

    Here are four stocks that offer good value and will likely outperform the majority of stocks throughout the broader market over the next several years.
  4. Investing News

    These 3 High-Quality Stocks Are Dividend Royalty

    Here are three resilient, dividend-paying companies that may mitigate some worry in an uncertain investing environment.
  5. Stock Analysis

    An Auto Stock Alternative to Ford and GM

    If you're not sure where Ford and General Motors are going, you might want to look at this auto investment option instead.
  6. Mutual Funds & ETFs

    The 4 Best Buy-and-Hold ETFs

    Explore detailed analyses of the top buy-and-hold exchange traded funds, and learn about their characteristics, statistics and suitability.
  7. Stock Analysis

    The Biggest Risks of Investing in Netflix Stock

    Examine the current state of Netflix Inc., and learn about three of the major fundamental risks that the company is currently facing.
  8. Stock Analysis

    What Seagate Gains by Acquiring Dot Hill Systems

    Examine the Seagate acquisition of Dot Hill Systems, and learn what Seagate is looking to gain by acquiring Dot Hill's software technology.
  9. Mutual Funds & ETFs

    What Exactly Are Arbitrage Mutual Funds?

    Learn about arbitrage funds and how this type of investment generates profits by taking advantage of price differentials between the cash and futures markets.
  10. Investing News

    Ferrari’s IPO: Ready to Roll or Poor Timing?

    Will Ferrari's shares move fast off the line only to sputter later?
  1. How do I read and analyze an income statement?

    The income statement, also known as the profit and loss (P&L) statement, is the financial statement that depicts the ... Read Full Answer >>
  2. Can working capital be too high?

    A company's working capital ratio can be too high in the sense that an excessively high ratio is generally considered an ... Read Full Answer >>
  3. How do I use discounted cash flow (DCF) to value stock?

    Discounted cash flow (DCF) analysis can be a very helpful tool for analysts and investors in equity valuation. It provides ... Read Full Answer >>
  4. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  5. What is the formula for calculating compound annual growth rate (CAGR) in Excel?

    The compound annual growth rate, or CAGR for short, measures the return on an investment over a certain period of time. Below ... Read Full Answer >>
  6. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>

You May Also Like

Trading Center
You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!